Products
Latest News
FAQ
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Newest First
Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events
Phase 4
Recruiting
Conditions
Ulcerative Colitis
Thromboembolism
Interventions
Drug: Infliximab Adalimumab y Golimumab
Drug: Tofacitinib
Subscribe
First Posted Date
2022-04-06
Last Posted Date
2023-11-18
Lead Sponsor
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Target Recruit Count
30
Registration Number
NCT05313620
Locations
🇪🇸
Hospital Universitario de La Princesa, Madrid, Spain
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy